Atazanavir for COVID-19
Atazanavir has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo, bioRxiv, doi:10.1101/2021.11.24.469775 ,
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.03.025 ,
Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909 ,
Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006 ,
Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947 ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.